Form FDA 483 Issued to Antonio R. Pizarro M.D., SFBC Fort Myers. 2005-06-03. Available from http://www.bioethicswatch.org/foia/sfbcinternational483_20050603.pdf (Forms FDA 483 issued to SFBC International Inc. courtesy of John Dorschner and the Miami Herald.)
Form FDA 483 Issued to Lisa A. Krinsky, SFBC International Inc. 2005-05-02. Available from http://www.bioethicswatch.org/foia/sfbcinternational483_20050502.pdf
Form FDA 483 Issued to Lisa A. Krinsky, SFBC International Inc. 2004-09-15. Available from http://www.bioethicswatch.org/foia/sfbcinternational483_20040915.pdf
Form FDA 483 Issued to Lisa A. Krinsky, SFBC International Inc. 2004-07-23. Available from http://www.bioethicswatch.org/foia/sfbcinternational483_20040723.pdf
Form FDA 483 Issued to James A. Holland M.D., Stratton VA Medical Center. 2003-01-02. Available from http://www.bioethicswatch.org/foia/strattonva483_20030102.pdf
Form FDA 483 Issued to Chi Van Dang M.D., Johns Hopkins School of Medicine Institutional Review Board. 2001-09-07. Available from http://www.fda.gov/ora/frequent/483s/jcciirb483.pdf
Form FDA 483 Issued to Chi Van Dang M.D., Johns Hopkins Bayview Medical Center Human Subjects Committee. 2001-09-07. Available from http://www.fda.gov/ora/frequent/483s/bayviewirb483.pdf
Form FDA 483 Issued to Alkis Togias M.D., Johns Hopkins Asthma & Allergy Clinic. 2001-06-28. Available from http://www.fda.gov/ora/frequent/483s/JohnHopkins483.html
Form FDA 483 Issued to L. Terry Chappell M.D., Great Lakes College of Clinical Medicine Institutional Review Board. 1999-12-01. Available from http://www.circare.org/foia2/483_glccm19991201.pdf
Form FDA 483 Issued to L. Terry Chappell M.D., Great Lakes Association of Clinical Medicine Institutional Review Board. 1994-12-21. Available from http://www.circare.org/foia2/483_glccm19941221.pdf
Form FDA 483 Issued to Paula R. Bickle Ph.D., Cascade Consultants Research Foundation. 1999-09-08. Available from http://www.circare.org/foia2/483_bickle.pdf
NDA 20-823 Novartis Exelon: Form FDA 483 Issued to Kevin L. Keim Ph.D., Quintiles Pacific, Inc. 1999-01-13. Available from http://www.bioethicswatch.org/foia/quintiles483_19990113.pdf
NDA 20-823 Novartis Exelon: El-Hage, A. Correspondence to Kevin L. Keim Ph.D., Quintiles Pacific, Inc. 1999-08-16. Available from http://www.circare.org/exelon/fda_quintiles_19990816.pdf (1)
Form FDA 483 Issued to Richard L. Borison M.D. 1997-04-22. Available from http://www.bioethicswatch.org/foia/borison483_19970422.pdf
Form FDA 483 Issued to Richard L. Borison M.D. 1993-06-24. Available from http://www.bioethicswatch.org/foia/borison483_19930624.pdf
Form FDA 483 Issued to Arnold E. Eggers M.D., SUNY Health Sciences Center. 1995-04-19. Available from http://www.bioethicswatch.org/foia/483_eggers.pdf
More Forms FDA 483: FDA Office of Regulatory Affairs / ORA Electronic Reading Room
Notes
1. NDA 20-823 Novartis Exelon, Administrative Documents and Correspondence. Accessed on 2007-06-01 at: http://www.fda.gov/cder/foi/nda/2000/20823_Exelon_admincorres.pdf
Last Updated: 2007-06-01
If you find the information on this page helpful please support CIRCARE with a tax-deductible contribution today. Because CIRCARE doesn't accept funds from pharmaceutical or medical device manufacturers, we depend on contributions from individuals like you to help us advocate for meaningful protection of human subjects in research. Donating on-line with PayPal is quick and easy. Find out more on our Support page
All material on this site © CIRCARE Incorporated (2002- ) or as indicated. Single copies can be downloaded for personal education. Adobe® Reader :: ::
